BAM
TCRT icon

Brave Asset Management’s Alaunos Therapeutics TCRT Stock Holding History

Brave Asset Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-52
Closed -$44K – 308
2016
Q3 		$44K Hold
52
– – 0.03% 226
2016
Q2 		$43K Sell
52
-42
-45% -$45.7K 0.03% 231
2016
Q1 		$105K Buy
94
+24
+34% +$24.6K 0.07% 171
2015
Q4 		$88K Hold
70
– – 0.06% 181
2015
Q3 		$95K Hold
70
– – 0.07% 168
2015
Q2 		$127K Buy
70
+9
+15% +$14K 0.09% 153
2015
Q1 		$98K Buy
+61
New +$90.4K 0.07% 171

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Brave Asset Management's TCRT Position: Q4 2016 in Review

Brave Asset Management sold out of Alaunos Therapeutics (TCRT) in Q4 2016, closing a stake of 52 shares — an estimated $44K sold.

Brave Asset Management first reported a position in TCRT in Q1 2015 and held it in 7 quarters. The position peaked at $127K in Q2 2015. 136 funds tracked by Wall St. Rank hold TCRT as of Q4 2016.

  • Brave Asset Management reported no remaining Alaunos Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Brave Asset Management sold 52 Alaunos Therapeutics shares in Q4 2016, an estimated $44K.
  • Brave Asset Management first reported a position in Alaunos Therapeutics in Q1 2015 and held it in 7 quarters.
  • Brave Asset Management's Alaunos Therapeutics position peaked at $127K in Q2 2015.
  • 136 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2016.

Based on Brave Asset Management's 13F filing for Q4 2016, filed 27 Jan 2017.